StreetAlpha.app
Home › Stocks › ENSC

Ensysce Biosciences, Inc. (ENSC)

$0.38
▼ −6.89%
LAST CLOSE · NOV 17

Ensysce Biosciences develops opioid pain medicines designed to resist abuse and overdose, based in La Jolla, California. It last closed at $0.38 on Nov 17, down 6.89% on the day.

AI Auto Pilots
Is ENSC in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$6.2M
+37.9% vs a year ago
Net income
−$91.0M
−1470.4% margin
EPS (diluted)
−$7.51
Operating margin
−1477.0%
−$91.4M operating income
Valuation
Market cap
$7.4M
19.5M shares
P/E
–
No P/E while losing money
Price to sales
1.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$29.7M
At Sep 30
Shareholder equity
$27.4M
Shares outstanding
19.5M
At Nov 11
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $3.5M$3.5MFY2021FY2022: $2.5M$2.5MFY2022FY2023: $2.2M$2.2MFY2023FY2024: $5.2M$5.2MFY2024FY2025: $5.1M$5.1MFY2025

From ENSC's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated ENSC in the past 90 days, not enough for a consensus
Average 12-month target
$2.00
▲ 424.5% upside

Based on 1 analyst who set a price target on ENSC in the past 90 days. The average target is $2.00, with a high of $2.00 and a low of $2.00, compared with the last close of $0.38.

Low $2.00Avg $2.00High $2.00
Blue marker: last close $0.38
Highest target$2.00
Average target$2.00
Lowest target$2.00
Latest rating changes
UBSInitiated
Nov 12Buy$2
DateFirmActionRatingPrice target
Nov 12UBSInitiatedBuy$2
Loading…

Whale Options Flow

90D

No whale options trades in ENSC in the last 90 days.

Loading…

See today’s whale options flow across the market →

ENSC Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ●9 buying vs 10 selling
  • ▲Held by funds +50.3 pts
  • ●Funds holding +0
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding18180.0%
In funds' top 1000–
Held by funds55.0%4.7%+50.3 pts
New / increased6 / 35 / 5−10.0%
Reduced / sold out5 / 51 / 2+233.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ENSC institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ENSC is in one of them and how their past ENSC trades turned out.

ENSC in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ENSC in an article yet. Here's the latest on the wider market.

About Ensysce Biosciences

Ensysce Biosciences is a pharmaceutical company based in La Jolla, California. It is developing pain medicines designed to reduce the risk of opioid misuse, abuse and overdose. Its lead candidate, PF614, is an oxycodone prodrug meant to provide pain relief while resisting abuse by injection, snorting and oral misuse. The company's product candidates are aimed at patients with acute or chronic pain and the prescribers who treat them.

Headquarters
La Jolla, CA